The Vitaria System delivers autonomic regulation therapy (ART) using vagus nerve stimulation. Credit: Manu5.

UK-based medical technology firm LivaNova has started implanting patients in the ANTHEM-HFrEF pivotal study with its Vitaria System for treating advanced heart failure.

The Vitaria System is designed to deliver autonomic regulation therapy (ART) through vagus nerve stimulation (VNS). The device is intended for patients who experience symptoms of heart failure even after guideline-directed medical therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“According to the company, Vitaria may be the first implantable active neurostimulation system intended for advanced heart failure treatment.”

In 2015, the system secured the European CE-Mark, while the US Food and Drug Administration (FDA) granted expedited access pathway designation last year.

ANTHEM-HFrEF is an international, multi-centre, randomised study designed to assess the safety and efficacy of autonomic regulation therapy delivered by the Vitaria System in around 800 subjects.

During the trial, the device will be implanted on the right cervical vagus nerve to deliver continuous, periodic VNS stimulation.

The first implant was carried out at UnityPoint Health – St. Luke’s Hospital in Cedar Rapids, Iowa, US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LivaNova Neuromodulation general manager Edward Andrle said: “Autonomic regulation therapy is based on our market-leading experience derived from VNS Therapy, which is used to treat other disorders.

“The ANTHEM-HFrEF pivotal study brings us closer to offering the Vitaria System to a large segment of the more than 20 million people currently battling heart failure around the world.”

According to the company, Vitaria may be the first implantable active neurostimulation system intended for advanced heart failure treatment if the system displays statistically and clinically meaningful improvements in certain pre-specified endpoints of heart failure symptoms, hospitalisation and survival during the study.

The pivotal trial is expected to be completed in December 2022.